Design and Application of a Home Care WeChat Mini-Program for Children After Congenital Heart Disease Surgery (CHD-HomeCare)

January 27, 2026 updated by: ruijie YangLan

Design and Application of a Home Care Mini-Program for Children With Congenital Heart Disease After Discharge: A Randomized Controlled Trial

This is a single-blind, randomized controlled trial aimed at evaluating the effectiveness of a family-centered, WeChat-based home care mini-program for children after congenital heart disease (CHD) surgery. Given the chronic nature of post-operative CHD management and the significant stress placed on families, this study shifts from a deficit-based to a strengths-based perspective, guided by the Double ABC-X model. Children (≤12 years old) who have undergone CHD surgery and their primary caregivers will be recruited. Participants will be randomly assigned to either the intervention group, which uses the mini-program for health education, peer support, and physiological monitoring, or the control group, which receives routine telephone follow-up. The primary outcomes are family health (measured by the Family Health Scale), family stress, and the quality of life for both the child and caregivers. Secondary outcomes include physiological parameters such as the 6-minute walk test distance. The study aims to provide evidence for a scalable digital health intervention to support long-term family adaptation and child recovery.

Study Overview

Detailed Description

  1. Background and Rationale Congenital heart disease (CHD) is the most common birth defect globally, with a high prevalence in China. While surgical advances have significantly improved survival rates, CHD has transitioned into a chronic condition requiring long-term management. The post-discharge period places immense stress on families, affecting caregiver well-being, family functioning, and the child's recovery. Existing home care models often focus on the child's deficits or rely on resource-intensive methods (e.g., home visits). Guided by the Double ABC-X model of family adaptation, this study adopts a family strengths-based perspective. It aims to develop and test a digital, interactive home care mini-program designed to support family resources, promote positive adaptation, and improve health outcomes after CHD surgery.
  2. Study Objectives Primary Objective: To evaluate the effectiveness of a family-centered, WeChat-based home care mini-program on improving family health in households with children after CHD surgery.

    Secondary Objectives: To assess the program's impact on: 1) reducing family stress, 2) enhancing the quality of life of both the child and primary caregivers, and 3) improving the child's physiological recovery indicators.

  3. Study Design This is a prospective, two-arm, parallel-group, assessor-blinded, randomized controlled trial (RCT). Participants will be randomly assigned in a 1:1 ratio to either the intervention group or the control group.
  4. Participants, Setting, and Timeline Participants: Families (the child who underwent surgery and their primary caregiver/parent) of children (≤12 years old) with CHD after surgical intervention.

    Setting: Recruitment and baseline assessment will be conducted at a tertiary hospital in Yunnan Province, China. The intervention and follow-up will be home-based.

    Sample Size: 210 families (105 per group), calculated with 80% power, a significance level of 0.05, an effect size (δ/σ) of 0.5, and accounting for 20% attrition.

    Timeline:

    Study Start Date (first enrollment): December 2025.

    Primary Completion Date (last participant's final data collection for primary outcome): December 2026.

    Study Completion Date: January 2027.

  5. Interventions

    Intervention Group: Will receive access to the "CHD Postoperative Home Care" WeChat mini-program in addition to routine care. The mini-program includes three core modules:

    Education Module: Provides multimedia (text, images, video) health information on post-operative care, nutrition, medication, activity guidance, and complication monitoring.

    Interactive Support Module: Features a secure peer-support community for sharing experiences (digital narrative therapy) and a direct communication channel for families to consult the healthcare team.

    Monitoring & Alert Module: Allows families to log and submit key health data (e.g., weight, symptoms). The system includes automated alerts for concerning values and prompts for scheduled follow-up assessments. The research team will remotely monitor this data and initiate follow-up calls if alerts are triggered.

    Control Group: Will receive routine postoperative care, which includes standard discharge instructions and scheduled telephone follow-ups by hospital staff at 1, 3, and 6 months post-discharge.

  6. Outcome Measures and Assessment Timepoints Assessments will occur at baseline (T0, pre-discharge) and at 1 (T1), 3 (T2), and 6 (T3) months post-discharge.

    Primary Outcomes:

    Family Health: Measured by the Chinese version of the Family Health Scale (FHS).

    Family Stress: Measured by the Congenital Heart Disease Family Stressor Scale.

    Quality of Life of Caregivers: Measured by the 36-Item Short Form Health Survey (SF-36).

    Quality of Life of the Child: Measured by the Chinese version of the Pediatric Quality of Life Inventory (PedsQL) Cardiac Module.

    Secondary Outcomes (Child Physiological Measures):

    Functional Capacity: 6-Minute Walk Test distance.

    Growth: Body weight.

    Cardiac Function: Heart rate and Left Ventricular Ejection Fraction (via echocardiogram).

  7. Randomization, Blinding, and Data Analysis

    Randomization: After baseline assessment, eligible families will be randomly assigned using computer-generated random numbers sealed in opaque envelopes.

    Blinding: Outcome assessors and data analysts will be blinded to group allocation. Due to the nature of the intervention, participants and intervention facilitators cannot be blinded.

    Statistical Analysis: Data will be analyzed using SPSS software. Baseline characteristics will be compared using t-tests, chi-square, or Mann-Whitney U tests. Primary and secondary outcomes will be analyzed using Linear Mixed Models (LMM) for repeated measures to examine group, time, and interaction effects.

  8. Ethical Considerations The study protocol has been submitted for approval to the Institutional Review Board of Kunming Medical University. Written informed consent will be obtained from all participating caregivers. The study will adhere to principles of confidentiality, beneficence, and the right to withdraw without penalty.

Study Type

Interventional

Enrollment (Estimated)

210

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Ruijie YangLan, Graduate Student
  • Phone Number: +86-18887278258
  • Email: 1052076436@qq.com

Study Contact Backup

Study Locations

    • Yunnan
      • Kunming, Yunnan, China, 650032
        • First Affiliated Hospital of Kunming Medical University
        • Contact:
          • Fang Ma, professor of nursing
          • Phone Number: +86 18887278258
          • Email: 1052076436@qq.com
        • Contact:
          • ruijie YangLan, postgraduate student
          • Phone Number: +86 18887278258
          • Email: 1052076436@qq.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • - The child is ≤12 years old.
  • The child has been diagnosed with congenital heart disease (CHD) and is scheduled for or has undergone corrective surgery.
  • The child is in a stable medical condition (non-acute phase).
  • At least one primary caregiver (parent or sibling >12 years old) of the child agrees to participate.
  • The caregiver provides written informed consent to participate in the study.

Exclusion Criteria:

  • - The child has severe developmental defects.
  • The child has other major diseases that significantly affect quality of life.
  • The caregiver has visual, hearing, or cognitive impairments that hinder communication.
  • The caregiver has a diagnosed psychiatric disorder.
  • The caregiver is unconscious or otherwise unable to provide consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Group
Participants receiving the WeChat mini-program intervention.
Participants in this group will receive standard post-discharge care as per hospital protocol, which includes initial discharge education and scheduled telephone follow-ups by hospital staff at 1, 3, and 6 months post-discharge to assess the child's status and answer questions.
Active Comparator: Control Group
Participants receiving routine care with telephone follow-up.
A family-centered WeChat mini-program providing health education, peer support, and remote monitoring for post-operative care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Family Health Score
Time Frame: Change from Baseline at 6 months post-discharge
Score on the Chinese version of the Family Health Scale (FHS).
Change from Baseline at 6 months post-discharge
Family Stress Score
Time Frame: Change from Baseline at 6 months post-discharge
Score on the Congenital Heart Disease Family Stressor Scale.
Change from Baseline at 6 months post-discharge
Child's Quality of Life Score
Time Frame: Change from Baseline at 6 months post-discharge
Score on the Chinese version of the Pediatric Quality of Life Inventory (PedsQL) Cardiac Module.
Change from Baseline at 6 months post-discharge
Caregiver's Quality of Life Score
Time Frame: Change from Baseline at 6 months post-discharge
Score on the 36-Item Short Form Health Survey (SF-36).
Change from Baseline at 6 months post-discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body Weight
Time Frame: Measured at 1, 3, and 6 months post-discharge
Body weight measured in kilograms.
Measured at 1, 3, and 6 months post-discharge
Left Ventricular Ejection Fraction
Time Frame: Measured at 6 months post-discharge
Percentage measured by echocardiogram.
Measured at 6 months post-discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Fang Ma,, professor of nursing, First Affiliated Hospital of Kunming Medical University
  • Principal Investigator: Fang Ma, professor of nursing, First Affiliated Hospital of Kunming Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 30, 2026

Primary Completion (Estimated)

July 30, 2026

Study Completion (Estimated)

March 30, 2027

Study Registration Dates

First Submitted

January 27, 2026

First Submitted That Met QC Criteria

January 27, 2026

First Posted (Actual)

February 4, 2026

Study Record Updates

Last Update Posted (Actual)

February 4, 2026

Last Update Submitted That Met QC Criteria

January 27, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Due to the sensitive nature of pediatric and family health data, individual participant data will not be shared publicly to protect participant confidentiality.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Congenital Heart Disease

Clinical Trials on Routine Care with Telephone Follow-up

Subscribe